Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α

J Med Chem. 2016 Apr 28;59(8):4026-31. doi: 10.1021/acs.jmedchem.6b00112. Epub 2016 Apr 14.

Abstract

The novel iridium(III) complex 1 was verified as a potent inhibitor of the TNF-α-TNFR protein-protein interaction in vitro and in cellulo. The iridium(III) center plays a critical role in organizing the structure of the bioactive metal complex, as the isolated ligands were found to be completely inactive. Both iridium enantiomers inhibited TNF-α-induced NF-κB activity and TNF-α-TNFR binding. 1 represents a promising scaffold for the further development of more potent organometallic TNF-α inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hep G2 Cells
  • Humans
  • Iridium / pharmacology*
  • NF-kappa B / metabolism
  • Protein Binding
  • Receptors, Tumor Necrosis Factor / metabolism
  • Signal Transduction
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • NF-kappa B
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Iridium